Iterum Historical Cash Flow
| ITRM Stock | USD 2.03 0.02 0.98% |
Analysis of Iterum Therapeutics cash flow over time is an excellent tool to project Iterum Therapeutics PLC future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 744.8 K or Change In Working Capital of 2.9 M as it is a great indicator of Iterum Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Iterum Therapeutics PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iterum Therapeutics PLC is a good buy for the upcoming year.
Iterum |
About Iterum Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Iterum balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Iterum's non-liquid assets can be easily converted into cash.
Iterum Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Iterum Therapeutics PLC to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Iterum Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Iterum Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Iterum Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Iterum Therapeutics' Depreciation is very stable compared to the past year. As of the 29th of November 2024, Change To Operating Activities is likely to grow to about 875.1 K, though Net Borrowings is likely to grow to (1.9 M).
Iterum Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Iterum Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Iterum Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 45.9M | 106.3M | 60K | 24.9M | 22.4M | 31.7M | |
| Investments | 40.1M | (11K) | (54.5M) | 14.0M | 14.2M | 14.9M | |
| Change In Cash | (39.8M) | 9.9M | 12.7M | (6.4M) | (15.0M) | (14.3M) | |
| Net Borrowings | (1.0M) | (5.5M) | (6.5M) | (2.3M) | (2.0M) | (1.9M) | |
| Stock Based Compensation | 2.2M | 2.8M | 4.3M | 4.8M | 784K | 744.8K | |
| Free Cash Flow | (78.9M) | (54.5M) | (15.9M) | (18.5M) | (39.3M) | (41.3M) | |
| Change In Working Capital | 17.9M | (24.6M) | (440K) | 2.3M | 2.8M | 2.9M | |
| Begin Period Cash Flow | 44.7M | 4.9M | 14.8M | 27.5M | 21.1M | 22.2M | |
| Total Cashflows From Investing Activities | 40.1M | (11K) | (54.6M) | 14.0M | 16.1M | 16.9M | |
| Other Cashflows From Financing Activities | 2.1K | (11K) | (54.6M) | 433K | 23.3M | 24.5M | |
| Depreciation | 152K | 161K | 2.1M | 1.8M | 1.8M | 1.8M | |
| Capital Expenditures | 24K | 11K | 61K | 62K | 13K | 12.4K | |
| Total Cash From Operating Activities | (78.9M) | (54.5M) | (15.8M) | (18.5M) | (39.3M) | (41.3M) | |
| Change To Operating Activities | 6.3M | (9.8M) | (774K) | 926K | 833.4K | 875.1K | |
| Net Income | (103.1M) | (52.0M) | (91.6M) | (44.4M) | (38.4M) | (40.3M) | |
| Total Cash From Financing Activities | (974K) | 64.5M | 83.1M | (1.8M) | 1.0M | 982.3K | |
| End Period Cash Flow | 4.9M | 14.8M | 27.5M | 21.1M | 6.1M | 5.8M | |
| Change To Netincome | 5.8M | 8.1M | 70.0M | 19.5M | 22.4M | 16.8M | |
| Change To Liabilities | 16.6M | (26.5M) | 63K | 1.9M | 1.7M | 1.8M | |
| Other Non Cash Items | 4.1M | 17.7M | 8.1M | 17.1M | (6.3M) | (5.9M) | |
| Issuance Of Capital Stock | 47.4M | 70.0M | 89.6M | 433K | 878K | 834.1K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.